Benefit-Risk Assessment in Clinical Development
Benefit-risk assessment in clinical trials can be challenging when treatments have benefits and risks across multiple outcomes. One2Treat uses Net Treatment Benefit (NTB) to help sponsors evaluate these outcomes together and quantify the overall treatment trade-off.
A quantitative approach
Traditional clinical trial analyses usually assess efficacy and safety outcomes separately. These analyses are essential, but when a treatment has both important benefits and risks, interpreting the overall balance can be difficult.
One2Treat Insights® applies Net Treatment Benefit to integrate multiple clinically relevant outcomes into a single treatment comparison. This provides an additional perspective on the overall benefit-risk profile alongside conventional endpoint analyses.
For example, a treatment may improve disease control while increasing serious adverse events. Rather than considering these findings independently, NTB can evaluate the predefined benefits and risks together to quantify how the treatments compare overall.
What is benefit-risk assessment?
Benefit-risk assessment is the structured evaluation of the benefits and risks associated with a medical treatment. It considers evidence across relevant outcomes to support an overall understanding of a treatment’s clinical profile.
The outcomes included will depend on the disease, treatment and patient population. They may include efficacy, survival, symptoms, quality of life, treatment burden and adverse events.
The challenge is that these outcomes are not always directly comparable. Their clinical importance can differ, and improving one outcome may come with a disadvantage in another.
A quantitative approach can help make these trade-offs more explicit.
The Net Treatment Benefit approach
Net Treatment Benefit is a measure based on Generalized Pairwise Comparisons that evaluates multiple outcomes simultaneously. It compares patients across treatments according to predefined outcomes and their relative importance.
NTB can account for both favourable and unfavourable outcomes, producing an overall measure of the treatment comparison.
This does not replace individual efficacy or safety analyses. Instead, it adds an integrated perspective that can help sponsors understand how multiple treatment effects combine.
How One2Treat supports benefit-risk assessment
With One2Treat Insights, sponsors can use clinical trial data to:
- Integrate multiple benefits and risks into one analysis
- Define the relative importance of different outcomes
- Quantify treatment trade-offs using Net Treatment Benefit
- Complement conventional efficacy and safety analyses
The result is a more integrated view of treatment effects that can support clinical development and benefit-risk discussions.
Benefit-risk assessment and regulatory decisions
A benefit-risk assessment should make the evidence and trade-offs underlying a treatment’s overall profile transparent. Quantitative approaches such as NTB can provide additional context for regulatory discussions by showing how multiple clinically relevant outcomes contribute to the overall treatment comparison.
The objective is not to “convince” regulators of a particular conclusion, but to provide a clear and reproducible analysis that supports evaluation of the totality of evidence.
Frequently asked questions about benefit-risk assessment
A benefit-risk assessment framework provides a structured approach for identifying relevant benefits and risks, evaluating the evidence for each, considering their clinical importance and assessing the overall trade-off.
It involves identifying clinically relevant benefits and risks, analysing treatment effects and uncertainty, and assessing how the different outcomes contribute to the overall treatment profile. Quantitative methods can be used where appropriate to examine trade-offs between outcomes.
A structured assessment can help communicate the evidence supporting a treatment’s overall clinical profile. It can make important trade-offs between benefits and risks more transparent and provide additional context alongside conventional analyses.
Quantitative benefit-risk assessment uses numerical methods to evaluate treatment benefits and risks. It can help quantify trade-offs that may be difficult to express through a purely qualitative assessment.
Net Treatment Benefit is a measure based on Generalized Pairwise Comparisons that integrates multiple outcomes into an overall comparison between treatments. It can account for both favourable and unfavourable outcomes.
Net Treatment Benefit (NTB) provides a quantitative way to integrate multiple efficacy, safety, and patient-reported outcomes into a single analysis. By considering the totality of the evidence and the relative importance of different outcomes, NTB can help market access teams better characterize the overall value of a treatment and communicate benefit-risk trade-offs to HTA bodies and other stakeholders. Incorporating patient preferences can further strengthen the assessment by reflecting which outcomes matter most to patients when evaluating treatment value.
